Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07275315 in adults with moderate-to-severe COPD
2024-518587-12-00Phase 2Authorised
- Sponsor
- Pfizer
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing PF-07275315 with Placebo (2 arms). Planned start Sep 2026; status: authorised.
02
Drugs
tilrekimig
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2024-518587-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518587-12-00.